$1.12 Billion is the total value of Rhenman & Partners Asset Management AB's 82 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 2.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $56,630,000 | +141.6% | 744,354 | +291.8% | 5.04% | +98.9% |
| NVCR | Buy | NOVOCURE LTD REG | $45,593,000 | +105.0% | 409,600 | +9.2% | 4.05% | +68.8% |
| UNH | Buy | UNITED HEALTH GROUP INC | $34,295,000 | +10.7% | 110,000 | +4.8% | 3.05% | -8.9% |
| GH | Buy | GUARDANT HEALTH INC REG | $26,827,000 | +78.7% | 240,000 | +29.7% | 2.38% | +47.1% |
| MYOK | Buy | MYOKARDIA INC | $25,903,000 | +67.6% | 190,000 | +18.8% | 2.30% | +37.9% |
| CI | Buy | CIGNA CORP NEW | $25,412,000 | +23.1% | 150,000 | +36.4% | 2.26% | +1.3% |
| ALXN | Buy | ALEXION PHARMACEUTICALS INC | $25,175,000 | +18.0% | 220,000 | +15.8% | 2.24% | -2.9% |
| HUM | Buy | HUMANA INC | $24,833,000 | +16.4% | 60,000 | +9.1% | 2.21% | -4.2% |
| LLY | Buy | LILLY ELI & CO | $24,423,000 | +41.7% | 165,000 | +57.1% | 2.17% | +16.6% |
| JAZZ | Buy | JAZZ PHARMACEUTICALS PLC | $24,240,000 | +60.3% | 170,000 | +24.1% | 2.16% | +32.0% |
| ANTM | Buy | ANTHEM INC | $24,173,000 | +41.4% | 90,000 | +38.5% | 2.15% | +16.4% |
| LVGO | Buy | LIVONGO HEALTH INC | $23,383,000 | +148.8% | 166,961 | +33.6% | 2.08% | +104.8% |
| MDT | Buy | MEDTRONIC PLC | $22,943,000 | +91.3% | 220,780 | +68.8% | 2.04% | +57.4% |
| ABT | Buy | ABBOTT LABS | $22,310,000 | +31.9% | 205,000 | +10.8% | 1.98% | +8.6% |
| COO | Buy | COOPER COS INC | $20,227,000 | +78.3% | 60,000 | +50.0% | 1.80% | +46.7% |
| BHVN | Buy | BIOHAVEN PHARMACTL HLDG CO L | $20,153,000 | +31.3% | 310,000 | +47.6% | 1.79% | +8.0% |
| ABMD | Buy | ABIOMED INC | $19,394,000 | +18.1% | 70,000 | +2.9% | 1.72% | -2.9% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $18,981,000 | +66.3% | 114,311 | +14.3% | 1.69% | +36.9% |
| GILD | Buy | GILEAD SCIENCES INC | $18,325,000 | +3.6% | 290,000 | +26.1% | 1.63% | -14.8% |
| CNC | Buy | CENTENE CORP DEL | $17,499,000 | +17.5% | 300,000 | +28.0% | 1.56% | -3.3% |
| BSX | Buy | BOSTON SCIENTIFIC CORP | $17,195,000 | +19.5% | 450,000 | +9.8% | 1.53% | -1.7% |
| ESPR | Buy | ESPERION THERAPEUTICS INC NE | $16,912,000 | -22.4% | 455,000 | +7.1% | 1.50% | -36.2% |
| NKTR | Buy | NEKTAR THERAPEUTICS | $16,590,000 | -9.3% | 1,000,000 | +26.6% | 1.48% | -25.4% |
| ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $14,560,000 | +58.3% | 100,000 | +61.0% | 1.30% | +30.3% |
| CVS | Buy | CVS HEALTH CORP | $14,016,000 | -5.0% | 240,000 | +5.7% | 1.25% | -21.8% |
| TMO | Buy | THERMO FISHER SCIENTIFIC INC | $13,246,000 | +92.4% | 30,000 | +57.9% | 1.18% | +58.3% |
| REGN | Buy | REGENERON PHARMACEUTICALS | $12,595,000 | +61.6% | 22,500 | +80.0% | 1.12% | +33.0% |
| BAX | Buy | BAXTER INTL INC | $12,465,000 | +52.4% | 155,000 | +63.2% | 1.11% | +25.3% |
| ZBH | Buy | ZIMMER BIOMET HOLDINGS INC | $11,163,000 | +64.1% | 82,000 | +43.9% | 0.99% | +35.1% |
| AERI | Buy | AERIE PHARMACEUTICALS INC | $10,005,000 | +14.9% | 850,000 | +44.1% | 0.89% | -5.4% |
| BIIB | Buy | BIOGEN INC | $9,361,000 | +105.8% | 33,000 | +94.1% | 0.83% | +69.5% |
| BDX | Buy | BECTON DICKINSON & CO | $8,144,000 | +62.1% | 35,000 | +66.7% | 0.72% | +33.3% |
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $6,788,000 | +26.0% | 225,000 | +36.4% | 0.60% | +3.8% |
| ADVM | Buy | ADVERUM BIOTECHNOLOGIES INC | $6,438,000 | -38.3% | 625,000 | +25.0% | 0.57% | -49.3% |
| ACCD | New | ACCOLADE INC | $5,896,000 | – | 151,674 | +100.0% | 0.52% | – |
| MYOV | Buy | MYOVANT SCIENCES LTD | $5,339,000 | +72.6% | 380,000 | +153.3% | 0.48% | +42.2% |
| MGTX | Buy | MEIRAGTX HOLDINGS PLC | $4,965,000 | +32.2% | 375,000 | +25.0% | 0.44% | +8.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-10-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.